Seres Therapeutics, Inc.
MCRB
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). Iā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.98
Price-1.96%
-$0.30
1Y
Price
Market Cap
$131.450m
Small
Price/Earnings 3y Avg5y Avg
17x
Premium
Premium
Financials Overview
Key metrics over the past few years+2639.0%
EBITDA Margin+2337.3%
Net Profit Margin+626.2%
Free Cash Flow MarginRevenue
$351k
-
1y CAGR-
3y CAGR-25.0%
5y CAGREarnings
$5.394m
+3866.2%
1y CAGR+1340.3%
3y CAGR+934.8%
5y CAGREPS
$0.61
+103.2%
1y CAGR+52.9%
3y CAGR-16.2%
5y CAGRBook Value
$43.697m
$143.473m
Assets$99.776m
Liabilities$85.253m
DebtDebt to Assets
59.4%
8.8x
Debt to EBITDAFree Cash Flow
-$23.368m
+84.3%
1y CAGR+37.6%
3y CAGR-2019.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company